OakChart

Nasus Pharma Ltd

NSRXHealthcare·Drug Manufacturers - General·Israel·Nano·AMEX·Nov 12 • 3:59 PM ET

2.82-0.09 (-3.09%)
2026-11-13 00:01 CET
Market cap
$33.03M
Revenue, TTM
0.00 USD m
Net income, TTM
-3.35 USD m
Free cash flow, TTM
-3.36 USD m
EPS diluted, TTM
-0.33
Price / earnings
-
Compare

Price

NSRX against its 20, 50 and 200-day averages
Terms2050200Earnings
Patternshover a marker to name it
EPS mean, own scale
RS 6EPS -1.13Price-1.13-0.733.004.005.00145K290KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NSRXclose 2.8220-day 3.1350-day 3.39200-day 3.492.82

70.3% under the 52-week high of 9.50 on 31 Dec 2025. 52-week low 1.98 on 31 Mar 2026. Last 15 sessions, 31.2% high to low

Volume 0.49× normal · the line is the 50-bar volume average

Setup. RS line 6
CANSLIM 0 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K

Profile

NSRX
52-week range, 11% of the way up
1.989.50

Nasus Pharma Ltd. engages in the development of intranasal drugs for emergency medical conditions. It offers Powder-Based Intranasal (PBI) specialized product portfolio, to address acute medical conditions and public health threats. The company was founded by Udi Gilboa and Dalia Megiddo in May 2019 and is headquartered in Tel Aviv, Israel.

Employees7
IPOAug 13, 2025
Beta4.23
ATR, 14d0.25
Rel volume0.49
Short float1.19%
Insider own49.21%
Inst own18.36%

Snapshot

6 groups

Valuation

Index-
Market Cap$33.03M
Enterprise Value29.06M
Income-3.35M
Sales0.00M
Book / share0.32
Cash / share0.34
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees7
IPOAug 13, 2025

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book8.95
Price / cash8.26
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio8.77
Current Ratio8.77
Debt / equity0.01
Long-term debt / equity0.01
Options and shortNo / Yes

Earnings

Earnings / share-0.33
Earnings next year-1.10
Earnings next quarter0.00
Earnings this year-55.14%
Earnings next year2.87%
Earnings growth, 5 years3.96%
Past earnings growth-49.37% -
Past sales growth- -
Earnings vs last year-
Sales vs last year-
Earnings vs last quarter-358.03%
Sales vs last quarter-
EarningsAug 17 BMO
Surprise- -

Ownership

Insiders own49.21%
Insider trades0.11%
Institutions own18.36%
Institution trades-8.22%
Return on assets-153.55%
Return on equity-278.36%
Return on capital-90.35%
Gross Margin-
Operating margin-
Profit Margin-
20-day average-9.78%
50-day average-16.85%
200-day average-19.13%

Technical

Shares out11.71M
Shares floating5.95M
Short / float1.19%
Short ratio4.09
Short interest0.07M
52-week high9.50 -70.3%
52-week low1.98 +42.4%
Volatility6.82% 8.62%
Average range0.25
Strength index36.01
Market sensitivity4.23
Relative volume0.49
Avg Volume17.38K
Volume8,563

Performance

Perf Week-3.09%
Perf Month-11.32%
Perf Quarter-22.10%
Perf Half Y-5.05%
Perf YTD-69.18%
Perf Year-62.85%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recommendation1.00
Target Price16.50
Prev Close2.91
Price2.82
Change %-3.09%

Peers

Mkt cap
TickerCompanyMkt cap
SPRYARS Pharmaceuticals Inc383.02M
AQSTAquestive Therapeutics Inc448.70M
EBSEmergent Biosolutions Inc302.84M
MIRAMira Pharmaceuticals Inc27.24M
VTRSViatris Inc23.70B
AMPHAmphastar Pharmaceuticals Inc1.23B
SCLXScilex Holding Company10.98M
TEVATeva- Pharmaceutical Industries Ltd50.93B
CPIXCumberland Pharmaceuticals Inc99.34M
ATRAptargroup Inc8.98B

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Teleman Dan BenjaminChief Executive OfficerJun 17 '26Buy3.106,55020,305163,541Jun 22 07:12 AM
Teleman Dan BenjaminChief Executive OfficerApr 22 '26Buy3.762,90010,904156,991Apr 22 09:44 PM
Teleman Dan BenjaminChief Executive OfficerMar 31 '26Buy2.0415,00030,60021,246Apr 01 07:31 AM

News

latest 14 of 56
  • Nasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026 (GlobeNewswire)
  • Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron (GlobeNewswire)
  • Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis (GlobeNewswire) +7.20%
  • Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Nasus Pharma Announces Transition of Chief Financial Officer (GlobeNewswire) +5.21%
  • Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth (GlobeNewswire)
  • Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum (GlobeNewswire)
  • Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003) (GlobeNewswire)
  • Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis (GlobeNewswire)
  • Nasus Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update (GlobeNewswire) +10.84%
  • Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen with Accelerated Speed to Therapeutic Threshold (GlobeNewswire) -38.00%
  • Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study (GlobeNewswire) -15.43%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S12026-08-17-0.540--0.540---
2025Q32025-12-03-0.140-0.210-0.0700.00-1
2025Q22025-09-03-0.090-----
2025Q4---0.380--0.002
2026S2---0.670---2

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-0.803-0.685-0.7300.000.00
2026FY--1.133--0.00
2027FY--1.100--0.00
2028FY--0.647--3.52
2029FY--0.115--15.07
2030FY-0.735--33.50

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026S2R2026-10-29100-0.61-0.61-0.61
2026S2E2026-10-29200-0.67-0.73-0.61
2026S2E2026-08-17100-0.73-0.73-0.73
2026FYS2026-10-293000.000.000.00
2026FYS2026-05-212000.000.000.00
2026FYS2026-02-251000.000.000.00
2026FYS2025-12-111000.000.000.00
2026FYR2026-11-03200-0.99-1.14-0.84
2026FYR2026-10-29210-0.99-1.14-0.84
2026FYR2026-08-20110-0.84-0.84-0.84
2026FYR2026-02-25100-0.93-0.93-0.93
2026FYR2025-12-11100-0.93-0.93-0.93
2026FYE2026-11-03400-1.13-1.28-0.84
2026FYE2026-10-31410-1.13-1.28-0.84

Estimate history

EPS, annual-0.057-0.032-0.046-0.188
Period2022202320242025
EPS, quarterly
Period
Sales, annual0000
Period2022202320242025
Sales, quarterly
Period
Shares, annual9.0159.0159.0159.015
Period2022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue0.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.00
Gross Profit0.000.000.000.000.00
Selling, General and Administrative Excl. Other3.231.420.290.310.61
Research and Development1.440.650.090.150.33
Other Operating Expense0.000.000.000.000.00
Operating Income-3.23-1.42-0.29-0.31-0.61
Interest Expense--0.010.010.01
Unusual Expense0.190.280.12-0.060.03
Net Income Before Taxes-3.35-1.68-0.42-0.27-0.64
Income Taxes0.000.000.000.000.00
Consolidated Net Income-3.35-1.68-0.42-0.27-0.64
Net Income From Continuing Operations-3.35-1.68-0.42-0.27-0.64
Net Income-3.35-1.70-0.41-0.28-0.51
EPS (Recurring)-0.29-0.17-0.04-0.04-0.05
EPS (Basic, Before Extraordinaries)-0.33-0.19-0.05-0.03-0.06
EPS (Diluted)-0.33-0.19-0.05-0.03-0.06
EBITDA-3.23-1.42-0.29-0.31-0.61
Non-Operating Income (Expense)0.060.01-0.00-0.01-0.00
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense0.260.130.000.01-
Shares Outstanding11.719.029.029.029.02
Market Capitalization34.0834.0867.09--

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S1
Total Revenue0.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.00
Gross Profit0.000.000.00
Selling, General and Administrative Excl. Other1.991.240.23
Research and Development0.850.590.08
Other Operating Expense0.000.000.00
Operating Income-1.99-1.24-0.23
Interest Expense0.00--
Unusual Expense0.000.190.09
Net Income Before Taxes-1.96-1.39-0.33
Income Taxes0.000.000.00
Consolidated Net Income-1.96-1.39-0.33
Net Income From Continuing Operations-1.96-1.39-0.33
Net Income-1.96-1.39-0.35
EPS (Recurring)-0.18-0.14-0.03
EPS (Basic, Before Extraordinaries)-0.18-0.15-0.04
EPS (Diluted)-0.18-0.15-0.04
EBITDA-1.99-1.24-0.23
Non-Operating Income (Expense)0.030.03-0.01
Stock Option Compensation Expense0.170.090.04
Shares Outstanding11.719.029.02
Market Capitalization34.0878.8167.09

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments1.360.090.060.05
Short Term Receivables0.000.000.000.00
Inventories0.000.000.000.00
Other Current Assets0.160.040.060.07
Total Current Assets1.520.130.120.12
Net Property, Plant & Equipment0.050.000.000.00
Total Investments and Advances0.000.000.000.00
Intangible Assets0.000.000.000.00
Other Assets0.000.070.000.00
Total Assets1.570.200.120.12
Short Term Debt Incl. Current Port. of LT Debt0.010.490.680.45
Accounts Payable0.260.180.180.22
Other Current Liabilities0.400.410.310.24
Total Current Liabilities0.681.081.180.91
Long Term Debt0.020.000.000.00
Provision for Risks Charges0.000.000.000.00
Other Liabilities0.000.000.000.00
Total Liabilities0.701.081.180.91
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00
Common Equity0.87-0.88-1.05-0.79
Total Shareholders Equity0.87-0.88-1.05-0.79
Accumulated Minority Interest0.000.000.000.00
Total Equity0.87-0.88-1.05-0.79
Total Liabilities & Stockholders Equity1.570.200.120.12
Book Value Per Share0.10-0.10-0.12-0.09
Tangible Book Value Per Share0.10-0.10-0.12-0.09
Full-Time Employees7545
Price to Book Ratio9.23-55.09--
Return on Assets-190.51-261.98-225.69-
Return on Invested Capital-190.46---
Quick Ratio2.240.120.100.13
Current Ratio2.240.120.100.13

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-3.38-1.68-0.42-0.27-0.64
Other Funds (Non Cash)0.410.380.13-0.050.14
Funds from Operations-2.97-1.31-0.29-0.32-0.50
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-0.39-0.120.110.050.14
Cash from Operating Activities-3.35-1.43-0.18-0.28-0.36
Capital Expenditures-0.01-0.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments-1.22-0.870.000.000.00
Purchase of Investments-1.22-0.870.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.00
Other Uses0.000.000.000.00-0.05
Other Sources0.000.000.000.000.00
Cash from Investing Activities-1.23-0.870.000.00-0.05
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock7.052.460.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock7.052.460.000.000.00
Proceedsfrom Stock Options7.052.460.000.000.00
Issuance or Reduction of Debt, Net0.030.130.210.290.44
Change in Long Term Debt0.030.130.210.270.29
Issuance of Long Term Debt0.030.130.210.270.29
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.07
Other Financing Activities Uses0.000.000.000.00-0.07
Cash from Financing Activities7.082.590.210.290.37
Exchange Rate Effect-0.00-0.00-0.000.00-0.00
Net Change in Cash2.500.280.030.01-0.04
Free Cash Flow-3.36-1.43-0.18-0.28-0.36
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S1
Cash & Short Term Investments4.001.360.07
Short Term Receivables0.000.000.00
Inventories0.000.000.00
Other Current Assets0.140.160.02
Total Current Assets4.131.520.09
Net Property, Plant & Equipment0.050.050.00
Total Investments and Advances0.000.000.00
Intangible Assets0.000.000.00
Other Assets0.000.000.10
Total Assets4.181.570.19
Short Term Debt Incl. Current Port. of LT Debt0.020.010.76
Accounts Payable0.120.260.20
Other Current Liabilities0.340.400.51
Total Current Liabilities0.470.681.47
Long Term Debt0.020.020.00
Other Liabilities0.000.000.00
Total Liabilities0.490.701.47
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value0.000.000.00
Common Equity3.690.87-1.28
Total Shareholders Equity3.690.87-1.28
Accumulated Minority Interest0.000.000.00
Total Equity3.690.87-1.28
Total Liabilities & Stockholders Equity4.181.570.19
Book Value Per Share0.320.10-0.14
Tangible Book Value Per Share0.320.10-0.14
Price to Book Ratio9.23-64.71-55.09
Return on Assets-153.55--
Return on Equity-278.36--
Return on Invested Capital-52.80-156.15-
Quick Ratio8.772.240.06
Current Ratio8.772.240.06

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S1
Net Income-1.96-1.42-0.33
Other Funds (Non Cash)0.150.260.13
Funds from Operations-1.80-1.16-0.20
Extraordinary Item0.000.000.00
Changes in Working Capital-0.18-0.200.08
Cash from Operating Activities-1.99-1.37-0.12
Capital Expenditures-0.00-0.000.00
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments-0.31-0.910.00
Purchase of Investments-0.31-0.910.00
Sale Or Maturity of Investments0.000.000.00
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities-0.31-0.910.00
Cash Dividends Paid0.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00
Change in Capital Stock4.482.570.00
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock4.482.570.00
Proceedsfrom Stock Options4.482.570.00
Issuance or Reduction of Debt, Net0.000.030.10
Change in Long Term Debt0.000.030.10
Issuance of Long Term Debt0.000.030.10
Reduction of Long Term Debt0.000.000.00
Net Financing Active Other Cash Flow0.000.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities4.482.600.10
Exchange Rate Effect0.00-0.00-0.00
Net Change in Cash2.180.32-0.02
Free Cash Flow-1.99-1.37-0.12

Revenue breakdown

Pharmaceutical Preparations2025: 1.24B
Israel2025: 1.24B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.19%0.1M6.0M17.67K
2026-10-151.35%0.1M6.0M16.24K
2026-09-301.31%0.1M6.0M15.80K
2026-09-151.35%0.1M6.0M15.27K
2026-08-311.47%0.1M6.0M20.82K
2026-08-143.72%0.1M3.9M27.06K
2026-07-314.13%0.2M3.9M36.38K
2026-07-155.99%0.2M2.9M68.37K
2026-06-306.04%0.2M2.9M71.11K
2026-06-156.21%0.2M2.9M216.61K
2026-05-296.03%0.2M2.9M213.22K
2026-05-155.42%0.2M2.9M205.91K
2026-04-303.88%0.1M2.9M203.51K
2026-04-152.27%0.1M2.9M172.84K
2026-03-313.39%0.1M2.9M168.94K
2026-03-130.39%0.0M2.9M6.36K
2026-02-270.30%0.0M2.9M5.98K
2026-02-130.18%0.0M2.9M6.03K
2026-01-300.15%0.0M2.9M5.93K
2026-01-150.08%0.0M2.9M5.08K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-19S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-10-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-08SEC
2026-09-233Initial statement of beneficial ownership of securities2026-09-19SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-18424B5SEC
2026-09-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-18SEC
2026-09-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-09-11EFFECTEffectiveness filing by commission orderSEC
2026-09-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-04SEC
2026-09-01F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-08-20EFFECTEffectiveness filing by commission orderSEC
2026-08-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-19SEC
2026-08-19POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-08-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-14SCHEDULE 13G/ASEC
2026-07-313Initial statement of beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-22SEC
2026-07-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-28SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-09SEC
2026-05-26S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-15SCHEDULE 13GSEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-22SEC
2026-04-07SCHEDULE 13GSEC
2026-04-014Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-03-31EFFECTEffectiveness filing by commission orderSEC
2026-03-273Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-273Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-273Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-273Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-0620.31K100
2026-050000
2026-0410.90K100
2026-0330.60K100
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BALYASNY ASSET MANAGEMENT L.P.10.43%
Cable Car Capital, LP7.15%
Velan Capital Investment Management LP4.17%
Hudson Bay Capital Management LP1.56%
Bleichroeder LP1.04%
CITADEL ADVISORS LLC0.26%
XTX Topco Ltd0.19%
RENAISSANCE TECHNOLOGIES LLC0.12%
MORGAN STANLEY0.01%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
-

OakChart. NSRX. Cached 15 minutes. Terms

Some panels did not load: ratings.